A phase I/II study of intravenous Rexin-G and Reximmune-C for cancer immunotherapy: The GeneVieve protocol.

2546 Background: Rexin-G (R-G) and Reximmune-C (R-C) are tumor-targeted retrovectors bearing a cytocidal cyclin G1 “knockout” construct and a controllable GM-CSF expression construct, respectively....